Kantonsspital St.Gallen
login

publications

Markus Joerger

title  
 
Adamina M, Joerger M. Dose-toxicity models in oncology. Expert Opin Drug Metab Toxicol 2011; 7:201-211.
   
Matter-Walstra K, Joerger M, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M. Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the Swiss health care system. Value Health 2011; 15:65-71.
   
Joerger M, Thuerlimann B, Savidan A, Frick H, Bouchardy C, Konzelmann I, Probst-Hensch N, Ess S. A Population-Based Study on the Implementation of Treatment Recommendations for Chemotherapy in Early Breast Cancer. Clin Breast Cancer 2011;.
   
Buikhuisen W A, Burgers J A, Vincent A D, Schellens J H M, Beijnen J H, Smit E F, Joerger M. Pemetrexed pathway-associated germline polymorphisms: a useful tool for treatment individualization?. J Clin Oncol 2010; 28:e482-3; author reply e484.
   
Joerger M, Riesen W F, Thuerlimann B. Bevacizumab-associated hyperlipoproteinemia type IIb in a patient with advanced invasive-ductal breast cancer. J Oncol Pharm Pract 2010;.
   
Joerger M, Matter-Walstra K, Früh M, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M. Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. Ann Oncol 2010; 22:567-74.
   
Joerger M, Huitema A D R, Krähenbühl S, Schellens J H M, Cerny T, Reni M, Zucca E, Cavalli F, Ferreri A J M. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. Br J Cancer 2010; 102:673-7.
   
Joerger M. Cancer chemotherapy: targeting folic acid synthesis. Cancer Manag Res 2010; 2:293-301.
   
Joerger M, Templeton A, Koeberle D, Engler H, Riesen W F, Thuerlimann B. Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonates. Cancer Chemother Pharmacol 2010;.
   
Ess S, Joerger M, Frick H, Probst-Hensch N, Vlastos G, Rageth C, Lütolf U, Savidan A, Thuerlimann B. Predictors of state-of-the-art management of early breast cancer in Switzerland. Ann Oncol 2010; 22:618-24.
   
Joerger M, Thuerlimann B, Huober J. Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment?. Ann Oncol 2010; 22:17-23.
   
Joerger M, Omlin A, Cerny T, Früh M. The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action. Current drug targets 2010; 11:37-47.
   
Templeton A, Thuerlimann B, Joerger M. Ixabepilon bei lokal fortgeschrittenem oder metastasiertem Mammakarzinom: Neue Behandlungsoptionen nach Taxanen und Anthrazyklinen. Schweizer Krebsbulletin 2009;114-117.
   
Joerger M. Neue Optionen endokriner Therapieindividualisierung? Pharmakogenetik bei Brustkrebs: Leading Opinions. Medizin für die Frau 2009; 1:28-30.
   
Boehm S, Rothermundt C, Hess D, Joerger M. Antiangiogenic Drugs in Oncology: A Focus on Drug Safety and the Elderly - A Mini-Review. Gerontology 2009;.
   
Joerger M, Thuerlimann B. Update of the BIG 1-98 Trial: where do we stand?. Breast 2009; 18 Suppl 3:S78-82.
   
Joerger M, Senn H J, Thuerlimann B. St. Gallen 2009 recommendations on the treatment of early breast cancer: consensus and controversy. magazine of european medical oncology 2009; 2:229-231.
   
Smit E F, Burgers S A, Biesma B, Smit H J M, Eppinga P, Dingemans A M C, Joerger M, Schellens J H, Vincent A, Van Zandwijk N, Groen H J M. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009; 27:2038-45.
   
Joerger M, Nuessli D, Henz S, Zaunbauer W, Cerny T, Cogliatti S B, Gillessen S. CT-diagnosed mesenteric alterations in patients with non-Hodgkin's lymphoma: a population-based study. Onkologie 2008; 31:514-9.
   
Ribi K, Bernhard J, Schuller J C, Weder W, Bodis S, Joerger M, Betticher D, Schmid R A, Stupp R, Ris H B, Stahel R A, Swiss Group For Clinical Cancer Research SAKK . Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes. Lung cancer (Amsterdam, Netherlands) 2008; 61:398-404.
   
Greuter S, Joerger M, Koeberle D. Adjuvante Therapie des Kolonkarzinoms. Onkologie 2007; 3:20-24.
   
Rohr L, Klaeser B, Joerger M, Kluckert J T, Cerny T, Gillessen S. Increased pulmonary FDG Uptake in Bleomycin-associated pneumonitis. Onkologie 2007;320-323.
   
Von Rohr L, Klaeser B, Joerger M, Kluckert T, Cerny T, Gillessen S. Increased pulmonary FDG uptake in bleomycin-associated pneumonitis. Onkologie 2007; 30:320-3.
   
Joerger M, Huitema A D R, Richel D J, Dittrich C, Pavlidis N, Briasoulis E, Vermorken J B, Strocchi E, Martoni A, Sorio R, Sleeboom H P, Izquierdo M A, Jodrell D I, Féty R, De Bruijn E, Hempel G, Karlsson M, Tranchand B, Schrijvers A H G J, Twelves C, Beijnen J H, Schellens J H M, EORTC-PAMM-NDDG . Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG. Clinical pharmacokinetics 2007; 46:1051-68.
   
Joerger M, Huitema A D R, Richel D J, Dittrich C, Pavlidis N, Briasoulis E, Vermorken J B, Strocchi E, Martoni A, Sorio R, Sleeboom H P, Izquierdo M A, Jodrell D I, Calvert H, Boddy A V, Hollema H, Féty R, Van Der Vijgh W J F, Hempel G, Chatelut E, Karlsson M, Wilkins J, Tranchand B, Schrijvers A H G J, Twelves C, Beijnen J H, Schellens J H M. Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. Clinical cancer research : an official journal of the American Association for Cancer Research 2007; 13:6410-8.
   
Joerger M, Kuhn M. Probleme langwirkender Betamimetika bei Asthma. Pharma-Kritik 2007; 29:.
   
Joerger M, Huitema A D R, Huizing M T, Willemse P H B, De Graeff A, Rosing H, Schellens J H M, Beijnen J H, Vermorken J B. Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study. British journal of clinical pharmacology 2007; 64:622-33.
   
Jermann M, Stahel R A, Salzberg M, Cerny T, Joerger M, Gillessen S, Morant R, Egli F, Rhyner K, Bauer J A, Pless M. A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma. Cancer chemotherapy and pharmacology 2006; 57:533-9.
   
Joerger M, Huitema A D R, Van Den Bongard H J G D, Baas P, Schornagel J H, Schellens J H M, Beijnen J H. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. British journal of clinical pharmacology 2006; 62:71-80.
   
Joerger M, Huitema A D R, Boogerd W, Van Der Sande J J, Schellens J H M, Beijnen J H. Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients. Basic & clinical pharmacology & toxicology 2006; 99:133-40.
   
Sparidans R W, Bosch T M, Joerger M, Schellens J H M, Beijnen J H. Liquid chromatography-tandem mass spectrometric assay for the analysis of uracil, 5,6-dihydrouracil and beta-ureidopropionic acid in urine for the measurement of the activities of the pyrimidine catabolic enzymes. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2006; 839:45-53.
   
Brouwers E E M, Tibben M M, Rosing H, Hillebrand M J X, Joerger M, Schellens J H M, Beijnen J H. Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate. Journal of mass spectrometry : JMS 2006; 41:1186-94.
   
Joerger M, Bosch T M, Doodeman V D, Beijnen J H, Smits P H M, Schellens J H M. Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers. European journal of clinical pharmacology 2006; 62:681-4.
   
Joerger M, Huitema A D R, Van Den Bongard D H J G, Schellens J H M, Beijnen J H. Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 2006; 12:2150-7.
   
Wuermli L, Joerger M, Henz S, Schmid H P, Riesen W F, Thomas G, Krek W, Cerny T, Gillessen S. Hypertriglyceridemia as a possible risk factor for prostate cancer. Prostate cancer and prostatic diseases 2005; 8:316-20.
   
Brouwers E E M, Tibben M M, Joerger M, Van Tellingen O, Rosing H, Schellens J H M, Beijnen J H. Determination of oxaliplatin in human plasma and plasma ultrafiltrate by graphite-furnace atomic-absorption spectrometry. Analytical and bioanalytical chemistry 2005; 382:1484-90.
   
Wuermli L, Joerger M, Henz S, Schmid H P, Riesen W F, Thomas G, Krek W, Cerny T, Gillessen S. Hypertriglyceridemia as a possible risk factor for prostate cancer. Prostate Cancer Prostatic Dis 2005; 8:316-320.
   
Diethelm M, Joerger M. Letale Polypharmazie bei einem Hypertoniker - Erwiderung. Deutsche medizinische Wochenschrift (1946) 2005; 130:413-414.
   
Joerger M, Huitema A D R, Meenhorst P L, Schellens J H M, Beijnen J H. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. Cancer chemotherapy and pharmacology 2005; 55:488-96.
   
Joerger M, Koeberle D, Neumann H P H, Gillessen S. Von Hippel-Lindau disease--a rare disease important to recognize. Onkologie 2005; 28:159-63.
   
Joerger M, Warzinek T, Klaeser B, Kluckert J T, Schmid H P, Gillessen S. Major tumor regression afrer paclitaxel and carboplatin polychemotherapy in a patient with advanced penile cancer. Urology 2004; 63:778-780.
   
Joerger M, Diethelm M. Letale Polypharmazie bei einem Hypertoniker: Lethal polypharmacy in a patient with arterial hypertension. Deutsche medizinische Wochenschrift (1946) 2004; 129:2714-6.
   
Gautschi O, Bigosch C, Huegli B, Jermann M, Marx A, Chassé E, Ratschiller D, Weder W, Joerger M, Betticher D C, Stahel R A, Ziegler A. Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004; 22:4157-64.
   
Joerger M, Warzinek T, Klaeser B, Kluckert J T, Schmid H P, Gillessen S. Major tumor regression after paclitaxel and carboplatin polychemotherapy in a patient with advanced penile cancer. Urology 2004; 63:778-80.
   
Dedes K J, Szucs T D, Bodis S, Joerger M, Lowy A, Russi E W, Steinert H C, Weder W, Stahel R A. Management and costs of treating lung cancer patients in a university hospital. PharmacoEconomics 2004; 22:435-44.
   
Joerger M, Schellens J H M, Beijnen J H. Therapeutic drug monitoring of non-anticancer drugs in cancer patients. Methods and findings in experimental and clinical pharmacology 2004; 26:531-45.
   
Walter R B, Joerger M, Pestalozzi B C. Gemcitabine-associated hemolytic-uremic syndrome. American journal of kidney diseases : the official journal of the National Kidney Foundation 2002; 40:E16.
   
Joerger M, Oehlschlegel C, Cerny T, Gillessen S. Postradiation high-grade myofibroblastic sarcoma of the prostate -- a rare entity of prostatic tumors -- responding to liposomal Doxorubicin. Onkologie 2002; 25:558-61.
   
Joerger M, Gunz A, Speich R, Pestalozzi B C. Gemcitabine-related pulmonary toxicity. Swiss medical weekly : official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology 2002; 132:17-20.
   
Joerger M, Kuhn M, Hartmann K. Entzugssymptome der modernen Antidepressiva. Schweizerische Aerztezeitung 2001; 83:.
   
Joerger M, Beer S, Kesselring J. Impact of neurorehabilitation on disability in patients with acutely and chronically disabling diseases of the nervous system measured by the Extended Barthel Index. Neurorehabilitation and neural repair 2001; 15:15-22.
   
Joerger M, Hartmann K, & Kuhn M (2009). Side Effects of Drugs Annual 31: Drugs acting on the respiratory tract. In Side Effects of Drugs Annual 31 (pp. 309). Oxford UK: Elsevier; Linacre House Jordan Hill.
   
Joerger M, Hartmann K, & Kuhn M (2008). Side Effects of Drugs Annual 30: Drugs acting on the respiratory tract. In Side Effects of Drugs Annual 30. Oxford UK: Elsevier; Linacre House Jordan Hill.
   
Joerger M, Hartmann K, & Kuhn M (2005). Side Effects of Drugs Annual 29: Drugs acting on the respiratory tract. In Side Effects of Drugs Annual 29. Oxford UK: Elsevier; Linacre House Jordan Hill.
   
Joerger M, Hartmann K, & Kuhn M (2005). Side Effects of Durgs Annual 28: Drugs acting on the respiratory tract. In Side Effects of Durgs Annual 28. Oxford UK: Elsevier; Linacre House Jordan Hill.
   
Pestalozzi B, & Joerger M (2003). Malignant liver tumors: Current and emerging therapies: Systematic treatment of hepatobiliary tumors. In Malignant liver tumors: Current and emerging therapies (pp. 91-99): Jones and Bartlett Publishers.
   
Kuhn M, Joerger M, & Hartmann K (2003). Side Effects of Drugs Annual 26: Drugs acting on the respiratory tract. In Side Effects of Drugs Annual 26. Oxford UK: Elsevier; Linacre House Jordan Hill.
   
Pestalozzi B, & Joerger M (2002). Oncologic Emergencies: Drug related emergencies. In Oncologic Emergencies: Oxford University Press.
   
Kuhn M, Joerger M, & Hartmann K (2001). Side Effects of Drugs Annual 24: Drugs acting on the respiratory tract. In Side Effects of Drugs Annual 24. Oxoford UK: Elsevier; Linacre House Jordan Hill.
   
Neumair P, Joos L, Warschkow R, Ess S, Hitz F, Früh M, Brutsche M, Baty F, Krähenbühl S, & Joerger M (2016). Chemotherapy is not superior to erlotinib in pretreated patients with advanced non-small cell lung cancer (NSCLC): A retrospective study: Abstrakt 169P. In J Thorac Oncol. 11(4 Suppl) (pp. 131): Elsevier.
   
 
page 2 of 2